Literature DB >> 18356472

Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation.

V A Nagar1, J R Ye, W H Ng, Y H Chan, F Hui, C K Lee, C C T Lim.   

Abstract

BACKGROUND AND
PURPOSE: Atypical and malignant meningiomas are uncommon tumors with aggressive behavior and higher mortality, morbidity, and recurrence compared with benign tumors. We investigated the utility of diffusion-weighted (DW) MR imaging to differentiate atypical/malignant from benign meningiomas and to detect histologic dedifferentiation to higher tumor grade.
MATERIALS AND METHODS: We retrospectively compared conventional and DW MR images (b-value 1000 s/mm(2)) acquired on a 1.5T clinical scanner between 25 atypical/malignant and 23 benign meningiomas. The optimal cutoff for the absolute apparent diffusion coefficient (ADC) and normalized ADC (NADC) ratio to differentiate between the groups was determined by using receiver operating characteristic (ROC) analysis.
RESULTS: Irregular tumor margins, peritumoral edema, and adjacent bone destruction occurred significantly more often in atypical/malignant than in benign meningiomas. The mean ADC of atypical/malignant meningiomas (0.66 +/- 0.13 x 10(-3) mm(2)/s) was significantly lower compared with benign meningiomas (0.88 +/- 0.08 x 10(-3) mm(2)/s; P < .0001). Mean NADC ratio in the atypical/malignant group (0.91 +/- 0.18) was also significantly lower than the benign group (1.28 +/- 0.11; P < .0001), without overlap between groups. ROC analysis showed that ADC and NADC thresholds of 0.80 x 10(-3) mm(2)/s and 0.99, respectively, had the best accuracy: at the NADC threshold of 0.99, the sensitivity and specificity were 96% and 100%, respectively. Two patients had isointense benign tumors on initial DW MR imaging, and these became hyperintense with the decrease in ADC and NADC below these thresholds when they progressed to atypical and malignant meningiomas on recurrence.
CONCLUSIONS: ADC and NADC ratios in atypical/malignant meningiomas are significantly lower than in benign tumors. Decrease in ADC and NADC on follow-up imaging may suggest dedifferentiation to higher tumor grade.

Entities:  

Mesh:

Year:  2008        PMID: 18356472      PMCID: PMC8118818          DOI: 10.3174/ajnr.A0996

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  41 in total

1.  Water ADC, extracellular space volume, and tortuosity in the rat cortex after traumatic injury.

Authors:  I Vorísek; M Hájek; J Tintera; K Nicolay; E Syková
Journal:  Magn Reson Med       Date:  2002-12       Impact factor: 4.668

Review 2.  Magnetic resonance imaging of meningiomas.

Authors:  C S Zee; T Chin; H D Segall; S Destian; J Ahmadi
Journal:  Semin Ultrasound CT MR       Date:  1992-06       Impact factor: 1.875

3.  Use of MR exponential diffusion-weighted images to eradicate T2 "shine-through" effect.

Authors:  J M Provenzale; S T Engelter; J R Petrella; J S Smith; J R MacFall
Journal:  AJR Am J Roentgenol       Date:  1999-02       Impact factor: 3.959

4.  Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.

Authors:  A Shino; S Nakasu; M Matsuda; J Handa; S Morikawa; T Inubushi
Journal:  J Neurosurg       Date:  1999-12       Impact factor: 5.115

5.  Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.

Authors:  Frank W Floeth; Dirk Pauleit; Michael Sabel; Gabriele Stoffels; Guido Reifenberger; Markus J Riemenschneider; Paul Jansen; Heinz H Coenen; Hans-Jakob Steiger; Karl-Josef Langen
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

6.  Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.

Authors:  Maosheng Xu; Siew Ju See; Wai Hoe Ng; Earnest Arul; Michael F Back; Tseng Tsai Yeo; C C Tchoyoson Lim
Journal:  Neurosurgery       Date:  2005-05       Impact factor: 4.654

7.  Rhabdoid transformation of tumor cells in meningiomas: a histologic indication of increased proliferative activity: report of four cases.

Authors:  J J Kepes; L A Moral; S B Wilkinson; A Abdullah; J F Llena
Journal:  Am J Surg Pathol       Date:  1998-02       Impact factor: 6.394

8.  Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance.

Authors:  M J Fulham; A Bizzi; M J Dietz; H H Shih; R Raman; G S Sobering; J A Frank; A J Dwyer; J R Alger; G Di Chiro
Journal:  Radiology       Date:  1992-12       Impact factor: 11.105

9.  Solitary fibrous tumor of the pleura: apparent diffusion coefficient (ADC) value and ADC map to predict malignant transformation.

Authors:  Tsutomu Inaoka; Koji Takahashi; Naoyuki Miyokawa; Yoshinobu Ohsaki; Tamio Aburano
Journal:  J Magn Reson Imaging       Date:  2007-07       Impact factor: 4.813

Review 10.  Radiotherapy for atypical or malignant intracranial meningioma.

Authors:  M F Milosevic; P J Frost; N J Laperriere; C S Wong; W J Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

View more
  53 in total

1.  Relation of apparent diffusion coefficient with Ki-67 proliferation index in meningiomas.

Authors:  Ozdil Baskan; Gokalp Silav; Fatih Han Bolukbasi; Ozlem Canoz; Serdar Geyik; Ilhan Elmaci
Journal:  Br J Radiol       Date:  2015-11-05       Impact factor: 3.039

2.  Dural-based lesions: is it a meningioma?

Authors:  Vitor Nagai Yamaki; Luis Filipe de Souza Godoy; Gabriela Alencar Bandeira; Leandro Tavares Lucato; Gustavo Correa Lordelo; Davi Jorge Fontoura Solla; Iuri Santana Neville; Manoel Jacobsen Teixeira; Wellingson Silva Paiva
Journal:  Neuroradiology       Date:  2021-01-18       Impact factor: 2.804

3.  Technetium Tc99m-tetrofosmin brain single-photon emission CT for the diagnosis of malignant meningiomas.

Authors:  G A Alexiou; S Voulgaris; S Tsiouris; A D Fotopoulos; A P Kyritsis; K S Polyzoidis
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-04       Impact factor: 3.825

Review 4.  "Dazed and diffused": making sense of diffusion abnormalities in neurologic pathologies.

Authors:  K M O'Connor; G Barest; T Moritani; O Sakai; A Mian
Journal:  Br J Radiol       Date:  2013-10-28       Impact factor: 3.039

5.  Fast spectroscopic multiple analysis (FASMA) for brain tumor classification: a clinical decision support system utilizing multi-parametric 3T MR data.

Authors:  Evangelia Tsolaki; Patricia Svolos; Evanthia Kousi; Eftychia Kapsalaki; Ioannis Fezoulidis; Konstantinos Fountas; Kyriaki Theodorou; Constantine Kappas; Ioannis Tsougos
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-07-15       Impact factor: 2.924

Review 6.  Role of diffusion-weighted imaging in skull base lesions: A pictorial review.

Authors:  Neetu Soni; Nishant Gupta; Yogesh Kumar; Manisha Mangla; Rajiv Mangla
Journal:  Neuroradiol J       Date:  2017-06-20

7.  The diagnostic value of using combined MR diffusion tensor imaging parameters to differentiate between low- and high-grade meningioma.

Authors:  Kerim Aslan; Hediye Pinar Gunbey; Leman Tomak; Lutfi Incesu
Journal:  Br J Radiol       Date:  2018-05-31       Impact factor: 3.039

8.  Diffusion Profiling via a Histogram Approach Distinguishes Low-grade from High-grade Meningiomas, Can Reflect the Respective Proliferative Potential and Progesterone Receptor Status.

Authors:  Georg Alexander Gihr; Diana Horvath-Rizea; Nikita Garnov; Patricia Kohlhof-Meinecke; Oliver Ganslandt; Hans Henkes; Hans Jonas Meyer; Karl-Titus Hoffmann; Alexey Surov; Stefan Schob
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

9.  Imaging and diagnostic advances for intracranial meningiomas.

Authors:  Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 10.  Modern meningioma imaging techniques.

Authors:  D Saloner; A Uzelac; S Hetts; A Martin; W Dillon
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.